Can HBsAg Be Used as a Viral Replication Marker in Chronic Hepatitis B Patients?
Journal Title: Viral Hepatitis Journal - Year 2017, Vol 23, Issue 2
Abstract
Objective: Monitoring hepatitis B virus (HBV) treatment responses and virus replication is performed with molecular tests. However, these tests are either expensive or invasive. A new and more practical marker is needed. We aimed to evaluate the correlation between serum hepatitis B surface antigen (HBsAg) and alanine aminotransferase (ALT) levels and HBV DNA level in hepatitis B e antigen (HBeAg) +/- patients and detect whether HBsAg can be used as a surrogate replication marker instead of HBV DNA. Material and Methods: A retrospective study was conducted in 59 chronic hepatitis B patients. Serum ALT, HBsAg and HBeAg levels and HBV DNA levels were recorded. The results were analysed with the Mann-Whitney U test and Spearman correlation coefficient. A p value of ≤0.05 was considered statistically significant. Sequential results were compared using Blant-Alpman plot. Results: The patients were grouped as HBeAg-positive (37.2%) and HBeAg-negative (62.8%). Serum ALT levels were elevated in 82% of HBeAg-positive and 70.2% of HBeAg-negative subjects. There was a statistically significant difference in HBsAg levels between the groups (p<0.05). However, there was no statistically significant difference in ALT and HBV DNA levels (p>0.05). A statistically significant negative correlation was detected between HBsAg and HBV DNA levels in HBeAg-positive patients. No correlation was found between HBsAg and HBV DNA levels in HBeAg-negative subjects (p<0.05). In both HBeAg-positive and -negative individuals, there was a positive correlation between serum ALT and HBV DNA levels (p<0.05). Blant-Alpman graph did not show an appropriate profile. Conclusion: We found a negative correlation between HBsAg and HBV DNA levels in HBeAg-positive patients. However, this correlation is not practical in monitoring treatment response and replication.
Authors and Affiliations
Emel UZUNOĞLU, Ahmet Melih ŞAHİN, Esin AVCI, Hakan KUTLU, Gökçe Gökçe GÜNTEPE
Keywords
Related Articles
- EP ID EP251836
- DOI 10.4274/vhd.73645
- Views 70
- Downloads 0
Hepatitis B Virus Carrying Drug-resistance Compensatory Mutations in Chronically Infected Treatment-naive Patients
Objective: The prevalence of hepatitis B virus (HBV) is highly variable throughout the world. Geographical regions are classified according to the prevalence of hepatitis B surface antigen in the general population as hi...
The Role of New Viral Biomarkers in Chronic Hepatitis B: Ready to Use in the Clinical Practice?
Recent advances have been made to develop and improve the serologic and molecular virologic tools for the diagnosis and optimal management of chronic hepatitis B (CHB) infection. Several biomarkers associated with the na...
Elbasvir/Grazoprevir Experience - A New Glance at HCV Treatment: Case Report
Hepatitis C is a viral disease having a worldwide importance and posing a risk for liver complications. With the new treatment options, it is easy to manage with higher rates of success. Among them, one of the most recen...
Circulating Glucose-Regulated Protein 78 Levels in Patients with Chronic Hepatitis B Infection
Objectives: The role of endoplasmic reticulum (ER) stress in the pathogenesis of hepatitis B virus (HBV) has been reported. However, serum levels of glucose-regulated protein (GRP) 78 which is an ER stress marker both in...
TNF-alpha 308 SNP Rs3091256 GG Genotype is Strongly Associated with Fibrosis in Patients with Chronic Hepatitis C
Objective: We aimed to review the influence of host genetic factors on the clinical course, treatment response as well as fibrosis progression in patients with viral hepatitis C genotype 1. Materials and Methods: Ninety...